Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma.

Journal for immunotherapy of cancer - 1 Oct 2022

Immisch Lena, Papafotiou George, Popp Oliver, Mertins Philipp, Blankenstein Thomas, Willimsky Gerald

Abstract excerpt

Diffuse midline glioma is the leading cause of solid cancer-related deaths in children with very limited treatment options. A majority of the tumors carry a point mutation in the histone 3 variant (H3.3) creating a potential HLA-A*02:01 binding epitope (H3.3K27M26-35). Here, we isolated an H3.3K27M-specific T cell receptor (TCR) from transgenic mice expressing a diverse human TCR repertoire. Despite a high...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CD8-Positive T-Lymphocytes
Share to Epitopes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glioma

Share to Histones

Share to HLA-A2 Antigen

Share to Immunotherapy

Share to Mice, Transgenic

Share to Receptors, Antigen, T-Cell

Source

Open in PubMed Open full text

Identifiers

PMID: 36302563
DOI: 10.1136/jitc-2022-005535
PMCID: PMC9621174

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma.PMID 36302563Read ↗

H3K27M Mutation Reshapes the Antigenic Landscape in Diffuse Midline GliomaSemantic proximity Read ↗

H3K27M neoepitope vaccination in diffuse midline glioma induces B and T cell responses across diverse HLA loci of a recovered patientSemantic proximity Read ↗

Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy.Semantic proximity Read ↗

Neoepitope-specific vaccination of a patient with diffuse midline glioma targeting H3K27M induces polyclonal B and T cell responses across diverse HLA allelesSemantic proximity Read ↗

A first-in-human peptide vaccine targeting H3K27M; encouraging early findings in 8 adults with diffuse midline glioma.Semantic proximity Read ↗

A H3K27M-targeted vaccine in adults with diffuse midline glioma.Semantic proximity Read ↗

K27M-mutant histone-3 as a novel target for glioma immunotherapySemantic proximity Read ↗

INTERCEPT H3: a multicenter phase I peptide vaccine trial for the treatment of H3-mutated diffuse midline gliomasSemantic proximity Read ↗

A road map for the treatment of pediatric diffuse midline glioma.Semantic proximity Read ↗

H3.3K27M Cooperates with Trp53 Loss and PDGFRA Gain in Mouse Embryonic Neural Progenitor Cells to Induce Invasive High-Grade Gliomas.Semantic proximity Read ↗

CRISPR-targeted display of functional T cell receptors enables engineering of enhanced specificity and prediction of cross-reactivitySemantic proximity Read ↗

Therapeutic efficacy of dendritic cell vaccination in a novel syngeneic mouse model of diffuse hemispheric glioma, H3 G34-mutant.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.